DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 1 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,548,403 | $30,427,932 | 21.55% |
| Atlas Venture Life Science Advisors, LLC | 7,608,394 | $90,844,224 | 11.30% |
| Nicholas Investment Partners, LP | 2,237,111 | $26,711,105 | 1.83% |
| RA Capital Management | 7,809,852 | $93,249,633 | 1.76% |
| DAFNA Capital Management LLC | 507,100 | $6,054,774 | 1.66% |
| BRAIDWELL LP | 3,361,813 | $40,140,047 | 1.31% |
| APIS CAPITAL ADVISORS, LLC | 90,000 | $1,074,600 | 1.08% |
| Logos Global Management LP | 650,000 | $7,761,000 | 1.06% |
| CVI Holdings, LLC | 80,000 | $955,200 | 1.00% |
| COMMODORE CAPITAL LP | 739,661 | $8,831,552 | 0.99% |